Nelarabine

As an important targeted drug in the field of T-cell malignancy treatment, nelarabine is a purine nucleoside analog, and it is the first therapeutic drug specifically targeting relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Its mechanism of action is to generate active triphosphate through intracellular phosphorylation, incorporate into the DNA synthesis process, and induce tumor cell apoptosis. It has clear survival benefits especially for patients tolerant to conventional chemotherapy regimens. The applicable population is mainly children aged 1 year and above and adult patients with T-ALL/T-LBL who have failed at least two chemotherapy regimens, filling the treatment gap for this type of rare hematological tumor.

The current global nelarabine market size is growing steadily. The global market size in 2023 was approximately USD 420 million, and the compound annual growth rate from 2024 to 2030 is expected to remain at around 3.8%. The growth drivers mainly come from the increased penetration rate of the pediatric T-ALL indication and the improved accessibility of drugs in emerging markets. In terms of competitive landscape, the original research product still occupies the major global market share at present, and no generic drug has been approved in China. Since the original research patent has expired, a number of domestic pharmaceutical companies have started the research and development of generic drugs, and the generic substitution space is considerable in the future.

The original research enterprise of nelarabine is GlaxoSmithKline, and the original research brand name is Arranon. Its core compound patents in major markets such as the United States and China all expired in 2021. The main dosage form approved for the original research product is injection, with a specification of 250mg/50mL. It has been included in the FDA Reference Listed Drug Catalog, and is also included in the *Catalog of Reference Preparations of Chemical Drugs* of China. Up to now, there is no nelarabine preparation approved for marketing in China, and there is no valid nelarabine API registration number in the public notification status on the API registration platform of CDE. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for nelarabine, most of which are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products meet the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can provide stable reference standard support for pharmaceutical companies in the research and development of nelarabine generic drugs, quality research and consistency evaluation work.